AIMS/HYPOTHESIS: Glitazones are powerful insulin sensitisers prescribed for the treatment of type 2 diabetes. Their use is, however, associated with fluid retention and an increased risk of congestive heart failure. We previously demonstrated that pioglitazone increases proximal sodium reabsorption in healthy volunteers. This study examines the effects of pioglitazone on renal sodium handling in individuals prone to insulin resistance, i.e. those with diabetes and/or hypertension. METHODS: In this double-blind randomised placebo-controlled four-way crossover study, we examined the effects of pioglitazone (45 mg daily during 6 weeks) or placebo on renal, systemic and hormonal responses to changes in sodium intake in 16 individuals, eight with type 2 diabetes and eight with hypertension. RESULTS:Pioglitazone was associated with a rapid increase in body weight and an increase in diurnal proximal sodium reabsorption, without any change in renal haemodynamics or in the modulation of the renin-angiotensin aldosterone system to changes in salt intake. A compensatory increase in brain natriuretic peptide levels was observed. In spite of sodium retention, pioglitazone dissociated the blood-pressure response to salt and abolished salt sensitivity in salt-sensitive individuals. CONCLUSIONS/ INTERPRETATION:Pioglitazone increases diurnal proximal sodium retention in diabetic and hypertensive individuals. These effects cause fluid retention and may contribute to the increased incidence of congestive heart failure with glitazones. TRIAL REGISTRATION: ClinicalTrial.gov NCT01090752 FUNDING: Hypertension Research Foundation Lausanne.
RCT Entities:
AIMS/HYPOTHESIS: Glitazones are powerful insulin sensitisers prescribed for the treatment of type 2 diabetes. Their use is, however, associated with fluid retention and an increased risk of congestive heart failure. We previously demonstrated that pioglitazone increases proximal sodium reabsorption in healthy volunteers. This study examines the effects of pioglitazone on renal sodium handling in individuals prone to insulin resistance, i.e. those with diabetes and/or hypertension. METHODS: In this double-blind randomised placebo-controlled four-way crossover study, we examined the effects of pioglitazone (45 mg daily during 6 weeks) or placebo on renal, systemic and hormonal responses to changes in sodium intake in 16 individuals, eight with type 2 diabetes and eight with hypertension. RESULTS:Pioglitazone was associated with a rapid increase in body weight and an increase in diurnal proximal sodium reabsorption, without any change in renal haemodynamics or in the modulation of the renin-angiotensin aldosterone system to changes in salt intake. A compensatory increase in brain natriuretic peptide levels was observed. In spite of sodium retention, pioglitazone dissociated the blood-pressure response to salt and abolished salt sensitivity in salt-sensitive individuals. CONCLUSIONS/ INTERPRETATION:Pioglitazone increases diurnal proximal sodium retention in diabetic and hypertensive individuals. These effects cause fluid retention and may contribute to the increased incidence of congestive heart failure with glitazones. TRIAL REGISTRATION: ClinicalTrial.gov NCT01090752 FUNDING: Hypertension Research Foundation Lausanne.
Authors: YouFei Guan; Chuanming Hao; Dae Ryong Cha; Reena Rao; Wendell Lu; Donald E Kohan; Mark A Magnuson; Reyadh Redha; Yahua Zhang; Matthew D Breyer Journal: Nat Med Date: 2005-07-10 Impact factor: 53.440
Authors: Anne Zanchi; Christine Perregaux; Marc Maillard; Daniel Cefai; Juerg Nussberger; Michel Burnier Journal: Am J Physiol Endocrinol Metab Date: 2006-07-11 Impact factor: 4.310
Authors: Hui Zhang; Aihua Zhang; Donald E Kohan; Raoul D Nelson; Frank J Gonzalez; Tianxin Yang Journal: Proc Natl Acad Sci U S A Date: 2005-06-14 Impact factor: 11.205
Authors: Ananda Basu; Michael D Jensen; Frances McCann; Debabrata Mukhopadhyay; Michael J Joyner; Robert A Rizza Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Volker Vallon; Edith Hummler; Timo Rieg; Oleh Pochynyuk; Vladislav Bugaj; Jana Schroth; Georges Dechenes; Bernard Rossier; Robyn Cunard; James Stockand Journal: J Am Soc Nephrol Date: 2009-01-21 Impact factor: 10.121
Authors: J Nussberger; T Fasanella d'Amore; M Porchet; B Waeber; D B Brunner; H R Brunner; L Kler; A N Brown; R J Francis Journal: J Cardiovasc Pharmacol Date: 1987-01 Impact factor: 3.105
Authors: William J Kostis; Javier Cabrera; W Craig Hooper; Paul K Whelton; Mark A Espeland; Nora M Cosgrove; Jerry Q Cheng; Yingzi Deng; Christine De Staerck; Meredith Pyle; Nisa Maruthur; Ingrid Reyes; Cheryl A M Anderson; Jie Liu; John B Kostis Journal: Hypertension Date: 2013-02-25 Impact factor: 10.190
Authors: Yang Yu; Bao-Jian Xue; Shun-Guang Wei; Zhi-Hua Zhang; Terry G Beltz; Fang Guo; Alan Kim Johnson; Robert B Felder Journal: Hypertension Date: 2015-06-22 Impact factor: 10.190
Authors: Mahesha H Gangadhariah; Blake W Dieckmann; Louise Lantier; Li Kang; David H Wasserman; Manuel Chiusa; Charles F Caskey; Jaime Dickerson; Pengcheng Luo; Jorge L Gamboa; Jorge H Capdevila; John D Imig; Chang Yu; Ambra Pozzi; James M Luther Journal: Diabetologia Date: 2017-03-28 Impact factor: 10.122
Authors: Jing Wu; Larry N Agbor; Shi Fang; Masashi Mukohda; Anand R Nair; Pablo Nakagawa; Avika Sharma; Donald A Morgan; Justin L Grobe; Kamal Rahmouni; Robert M Weiss; James A McCormick; Curt D Sigmund Journal: Cardiovasc Res Date: 2021-01-01 Impact factor: 13.081